FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969129043> ?p ?o ?g. }

• W1969129043 endingPage "348" @default.
• W1969129043 startingPage "338" @default.
• W1969129043 abstract "Alemtuzumab is a humanised monoclonal antibody that depletes lymphocytes, causing long-term immunomodulation. In a 3-year, rater-blinded phase 2 study (the CAMMS223 study) in patients with relapsing-remitting multiple sclerosis (RRMS), alemtuzumab reduced relapse rate and the risk of sustained accumulation of disability compared with subcutaneous interferon beta-1a, and the mean expanded disability status scale (EDSS) score of the alemtuzumab cohort improved compared with baseline. Adverse events included infusion-associated reactions, predominantly mild to moderate infections, thyroid disorders, and immune thrombocytopenia. In this study, we further analysed the CAMMS223 data with the aim of determining whether demographic and baseline disease-related characteristics affect the beneficial effects of alemtuzumab. Additionally, we aimed to describe a new outcome measure in multiple sclerosis research: sustained reduction in disability.334 treatment-naive patients with active, early RRMS were randomly assigned in a 1:1:1 ratio to receive interferon beta-1a (44 μg subcutaneously three times per week), or 24 mg per day or 12 mg per day alemtuzumab intravenously for 2 or 3 annual cycles. We analysed freedom from clinical disease activity (CDA; defined as no relapses and no sustained accumulation of disability) and occurrence of sustained reduction in disability (SRD; a ≥1 point decrease on the EDSS sustained for 6 consecutive months for patients with a baseline EDSS ≥2), and analysed efficacy outcomes for subgroups based on age, sex, geographic region, MRI-T1 brain volume, MRI-T2 lesion volume, disease duration, number of previous relapses within 2 years, and EDSS.322 patients were analysed. 161 of 215 patients treated with alemtuzumab were free of CDA at 36 months (Kaplan-Meier estimate 71·8%, 95% CI 63·1-78·8%) compared with 52 of 107 patients treated with interferon beta-1a (42·6%, 32·4-52·4%; hazard ratio [HR]=0·31, 0·20-0·46; p<0·0001). For the 199 patients with a baseline EDSS score greater than or equal to 2, SRD was more likely (HR=2·61, 1·54-4·43; p=0·0004) among patients treated with alemtuzumab (66 of 133 patients, Kaplan-Meier estimate 51·6%, 95% CI 43·2-60·7%) than patients treated with interferon beta-1a (15 of 66 patients, 27·2%, 17·2-41·4%). All disability and relapse outcomes showed evidence of beneficial effects of alemtuzumab compared with interferon beta-1a across all analysed patient subsets, and no subgroup of patients consistently responded better than others to alemtuzumab.Alemtuzumab reduced disease activity compared with interferon beta-1a in most of the analysed subgroups. Significantly greater numbers of patients experienced sustained improvement in disability after treatment with alemtuzumab than interferon beta-1a. The efficacy offered by alemtuzumab is a substantial advance in the treatment of multiple sclerosis.Genzyme and Bayer Schering Pharma." @default.
• W1969129043 created "2016-06-24" @default.
• W1969129043 creator A5006728252 @default.
• W1969129043 creator A5008022339 @default.
• W1969129043 creator A5009824403 @default.
• W1969129043 creator A5020016996 @default.
• W1969129043 creator A5027429610 @default.
• W1969129043 creator A5029378745 @default.
• W1969129043 creator A5033288469 @default.
• W1969129043 creator A5057332951 @default.
• W1969129043 creator A5062032887 @default.
• W1969129043 creator A5065830564 @default.
• W1969129043 creator A5069330822 @default.
• W1969129043 creator A5069727178 @default.
• W1969129043 creator A5077624452 @default.
• W1969129043 creator A5080396033 @default.
• W1969129043 date "2011-04-01" @default.
• W1969129043 modified "2023-09-26" @default.
• W1969129043 title "Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes" @default.
• W1969129043 cites W1666336517 @default.
• W1969129043 cites W1780319921 @default.
• W1969129043 cites W1975254445 @default.
• W1969129043 cites W2094875942 @default.
• W1969129043 cites W2101483035 @default.
• W1969129043 cites W2105053272 @default.
• W1969129043 cites W2106948231 @default.
• W1969129043 cites W2112165124 @default.
• W1969129043 doi "https://doi.org/10.1016/s1474-4422(11)70020-5" @default.
• W1969129043 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21397567" @default.
• W1969129043 hasPublicationYear "2011" @default.
• W1969129043 type Work @default.
• W1969129043 sameAs 1969129043 @default.
• W1969129043 citedByCount "126" @default.
• W1969129043 countsByYear W19691290432012 @default.
• W1969129043 countsByYear W19691290432013 @default.
• W1969129043 countsByYear W19691290432014 @default.
• W1969129043 countsByYear W19691290432015 @default.
• W1969129043 countsByYear W19691290432016 @default.
• W1969129043 countsByYear W19691290432017 @default.
• W1969129043 countsByYear W19691290432018 @default.
• W1969129043 countsByYear W19691290432019 @default.
• W1969129043 countsByYear W19691290432020 @default.
• W1969129043 countsByYear W19691290432021 @default.
• W1969129043 countsByYear W19691290432022 @default.
• W1969129043 countsByYear W19691290432023 @default.
• W1969129043 crossrefType "journal-article" @default.
• W1969129043 hasAuthorship W1969129043A5006728252 @default.
• W1969129043 hasAuthorship W1969129043A5008022339 @default.
• W1969129043 hasAuthorship W1969129043A5009824403 @default.
• W1969129043 hasAuthorship W1969129043A5020016996 @default.
• W1969129043 hasAuthorship W1969129043A5027429610 @default.
• W1969129043 hasAuthorship W1969129043A5029378745 @default.
• W1969129043 hasAuthorship W1969129043A5033288469 @default.
• W1969129043 hasAuthorship W1969129043A5057332951 @default.
• W1969129043 hasAuthorship W1969129043A5062032887 @default.
• W1969129043 hasAuthorship W1969129043A5065830564 @default.
• W1969129043 hasAuthorship W1969129043A5069330822 @default.
• W1969129043 hasAuthorship W1969129043A5069727178 @default.
• W1969129043 hasAuthorship W1969129043A5077624452 @default.
• W1969129043 hasAuthorship W1969129043A5080396033 @default.
• W1969129043 hasConcept C126322002 @default.
• W1969129043 hasConcept C142724271 @default.
• W1969129043 hasConcept C197934379 @default.
• W1969129043 hasConcept C203014093 @default.
• W1969129043 hasConcept C204787440 @default.
• W1969129043 hasConcept C27081682 @default.
• W1969129043 hasConcept C2779015954 @default.
• W1969129043 hasConcept C2780640218 @default.
• W1969129043 hasConcept C2780892749 @default.
• W1969129043 hasConcept C2908698914 @default.
• W1969129043 hasConcept C2911091166 @default.
• W1969129043 hasConcept C2994247566 @default.
• W1969129043 hasConcept C3020694758 @default.
• W1969129043 hasConcept C67761136 @default.
• W1969129043 hasConcept C71924100 @default.
• W1969129043 hasConceptScore W1969129043C126322002 @default.
• W1969129043 hasConceptScore W1969129043C142724271 @default.
• W1969129043 hasConceptScore W1969129043C197934379 @default.
• W1969129043 hasConceptScore W1969129043C203014093 @default.
• W1969129043 hasConceptScore W1969129043C204787440 @default.
• W1969129043 hasConceptScore W1969129043C27081682 @default.
• W1969129043 hasConceptScore W1969129043C2779015954 @default.
• W1969129043 hasConceptScore W1969129043C2780640218 @default.
• W1969129043 hasConceptScore W1969129043C2780892749 @default.
• W1969129043 hasConceptScore W1969129043C2908698914 @default.
• W1969129043 hasConceptScore W1969129043C2911091166 @default.
• W1969129043 hasConceptScore W1969129043C2994247566 @default.
• W1969129043 hasConceptScore W1969129043C3020694758 @default.
• W1969129043 hasConceptScore W1969129043C67761136 @default.
• W1969129043 hasConceptScore W1969129043C71924100 @default.
• W1969129043 hasFunder F4320307772 @default.
• W1969129043 hasFunder F4320323589 @default.
• W1969129043 hasIssue "4" @default.
• W1969129043 hasLocation W19691290431 @default.
• W1969129043 hasLocation W19691290432 @default.
• W1969129043 hasOpenAccess W1969129043 @default.
• W1969129043 hasPrimaryLocation W19691290431 @default.
• W1969129043 hasRelatedWork W1969129043 @default.

• next